Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

TNFRSF8 positive

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

TNFRSF8 positive	Cutaneous T-cell Lymphoma	TNFRSF8 positive	Cutaneous T-cell Lymphoma	brentuximab vedotin Sensitive: A1 - Approval SOHO 2023 - 3 weeks (New C4) brentuximab vedotin Sensitive : A1 SOHO 2023 - 3wk	brentuximab vedotin Sensitive: A1 - Approval SOHO 2023 - 3 weeks brentuximab vedotin Sensitive : A1 SOHO 2023 - 3 weeks - (New C4)
TNFRSF8 positive	Hodgkin Lymphoma	TNFRSF8 positive	Hodgkin Lymphoma	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1
TNFRSF8 positive	Diffuse Large B Cell Lymphoma	TNFRSF8 positive	Diffuse Large B Cell Lymphoma	brentuximab vedotin Sensitive: A2 - Guideline brentuximab vedotin Sensitive : A2	brentuximab vedotin Sensitive: A2 - Guideline brentuximab vedotin Sensitive : A2
TNFRSF8 positive	Peripheral T-cell Lymphoma	TNFRSF8 positive	Peripheral T-cell Lymphoma	brentuximab vedotin Sensitive: A2 - Guideline brentuximab vedotin Sensitive : A2	brentuximab vedotin Sensitive: A2 - Guideline brentuximab vedotin Sensitive : A2
TNFRSF8 positive	Non-Hodgkin’s Lymphoma	TNFRSF8 positive	Non-Hodgkin’s Lymphoma	TT11 Sensitive: C2 – Inclusion Criteria TT11 Sensitive : C2	TT11 Sensitive: C2 – Inclusion Criteria TT11 Sensitive : C2
TNFRSF8 positive	Lymphoma	TNFRSF8 positive	Lymphoma	AFM13 Sensitive: C2 – Inclusion Criteria AFM13 Sensitive : C2	AFM13 Sensitive: C2 – Inclusion Criteria AFM13 Sensitive : C2
TNFRSF8 positive	Hodgkin Lymphoma	TNFRSF8 positive	Hodgkin Lymphoma	AFM13 Sensitive: C2 – Inclusion Criteria AFM13 Sensitive : C2	AFM13 Sensitive: C2 – Inclusion Criteria AFM13 Sensitive : C2
TNFRSF8 positive	Hodgkin Lymphoma	TNFRSF8 positive	Hodgkin Lymphoma	TT11 Sensitive: C3 – Early Trials TT11 Sensitive : C3	TT11 Sensitive: C3 – Early Trials TT11 Sensitive : C3
TNFRSF8 positive	Peripheral T-cell Lymphoma	TNFRSF8 positive	Peripheral T-cell Lymphoma	BV-ICE Sensitive: C3 – Early Trials BV-ICE Sensitive : C3	BV-ICE Sensitive: C3 – Early Trials BV-ICE Sensitive : C3
TNFRSF8 positive	Hodgkin Lymphoma	TNFRSF8 positive	Hodgkin Lymphoma	CD30-targeted CAR-T immunotherapy Sensitive: C3 – Early Trials CD30-targeted CAR-T immunotherapy Sensitive : C3	CD30-targeted CAR-T immunotherapy Sensitive: C3 – Early Trials CD30-targeted CAR-T immunotherapy Sensitive : C3
TNFRSF8 positive	Non-Hodgkin’s Lymphoma	TNFRSF8 positive	Non-Hodgkin’s Lymphoma	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3
TNFRSF8 positive	Lymphoma	TNFRSF8 positive	Lymphoma	T-lymphocyte cell therapy Sensitive: D – Preclinical T-lymphocyte cell therapy Sensitive : D	T-lymphocyte cell therapy Sensitive: D – Preclinical T-lymphocyte cell therapy Sensitive : D
TNFRSF8 positive	Non-Hodgkin’s Lymphoma	TNFRSF8 positive	Non-Hodgkin’s Lymphoma	McSAF 02 Sensitive: D – Preclinical McSAF 02 Sensitive : D	McSAF 02 Sensitive: D – Preclinical McSAF 02 Sensitive : D
TNFRSF8 positive	Lymphoma	TNFRSF8 positive	Lymphoma	brentuximab vedotin + SGN-CD30C Sensitive: D – Preclinical brentuximab vedotin + SGN-CD30C Sensitive : D	brentuximab vedotin + SGN-CD30C Sensitive: D – Preclinical brentuximab vedotin + SGN-CD30C Sensitive : D